

SUMÁRIO/CONTENTS

Mensagem de Boas-Vindas	3
Comissão Científica e Comissão Organizadora do Congresso	4
Programa Científico	6

SESSÕES

SESSÃO DE ABERTURA	20
• A arte na medicina Manuel Valente Alves	20
SESSÃO I – HOT TOPICS EM SÍNDROMES DE FRAGILIDADE	20
• Palestra 1: Sarcopenia e síndromes de fragilidade do idoso Carlos Vaz	20
• Palestra 2: Desafios atuais na terapêutica da osteoporose Viviana Tavares	20
SESSÃO II – ASPETOS CLÍNICOS NAS ESPONDILARTRITES	21
• Palestra 1: Bone in Ankylosing Spondylitis Helena Santos	21
• Palestra 2: Axial Spondyloarthritis in clinical practice Désirée van der Heijde	21
SESSÃO III – ASPETOS CLÍNICOS NA ARTRITE REUMATÓIDE	21
• Palestra 1: Epigenética Alain Cantagrel	21
• Palestra 2: Gestão do risco cardiovascular na Artrite Reumatóide José António Pereira da Silva	22
SESSÃO IV – CONETIVITES/DOENÇAS SISTÉMICAS REUMÁTICAS	22
• Palestra 1: What is new in the diagnosis and treatment of large vessel vasculitis? Cristina Ponte	22
• Palestra 2: Estado da arte em Esclerodermia Marco Matucci Cerinic	22
SESSÃO V – OSTEOARTROSE DIA A DIA	22
• Palestra 1: Osteoarthritis daily life – How can rheumatologists make a difference? Ana M. Rodrigues	22
• Palestra 2: Mitos e realidades no tratamento da Osteoartrose Margarida Cruz	23

CONFERÊNCIAS

Conferência 1 – Sexualidade e doenças reumáticas	26
Maria do Céu Santo	
Conferência 2 – Utilização <i>off-label</i> de terapêuticas biológicas em idade pediátrica	26
Maria José Santos	

SUMÁRIO/CONTENTS

COMUNICAÇÕES ORAIS

SESSÃO I	28
CO15 – The role of individual and country-level socio-economic factors in work participation in patients with spondyloarthritis across 22 countries worldwide: results from the COMOSPA Study	28
CO188 – Proportion of hip and non-hip major fractures: costs and quality of life	29
CO179 – Incidência de fratura da extremidade proximal do fémur em mulheres pós-menopáusicas e a mortalidade pós-evento – estudo de uma população do interior de Portugal	30
SESSÃO II	31
CO165 – 2016 Update of the ASAS-EULAR management recommendations for axial spondyloarthritis	31
CO25 – Safety and efficacy of certolizumab pegol over 204 weeks in patients with axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis	32
CO36 – The GO-DACT protocol: a randomized controlled trial to compare the efficacy of golimumab in combination with methotrexate (mtx) versus mtx monotherapy, in improving dactylitis and enthesitis, in mtx naïve psoriatic arthritis patients	34
SESSÃO III	
CO139 – Performance of SLEDAI-2K to detect a clinically meaningful change in sle disease activity: a 36-month prospective cohort study of 334 patients	35
CO106 – Influence of patient global assessment on the disease activity assessment in patients with rheumatoid arthritis: a meteor cross-sectional study	36
CO149 – Drug survival of the first biologic in rheumatoid arthritis and predictors thereof in real world clinical practice	37
SESSÃO IV	38
CO41 – Persistence with first biological agent and reasons for discontinuation in patients with juvenile idiopathic arthritis: data from the portuguese register, Reuma.pt	38
CO177 – Efficacy and safety of tumour necrosis factor antagonists in a large cohort of juvenile dermatomyositis patients	39
CO73 – Reuma.pt/vasculitis – two years existence of the portuguese vasculitis registry	40
SESSÃO V	42
CO63 – Role of ultrasound in the assessment of the carpal tunnel syndrome: should we go more distal?	42
CO89 – Ultrasound assessment of skin thickness in systemic sclerosis patients: correlation with clinical features	43
CO163 – Undifferentiated connective tissue diseases – how do they differentiate over 10 years?	44
<hr/> MESAS SPR <hr/>	
MESA SPR – NOVARTIS	50
“IL-17A Inhibition - Challenging the Treatment Paradigm in SpA”	50
MODERADORES: Fernando Pimentel dos Santos e Carlos Vaz	
• The IL-17A Journey in SpA: From theory to proof-of-concept Dhaval Kumar Patel	50
• Secucinumab in SpA: From proof-of-concept to clinical practice Frank Behrens	50

SUMÁRIO/CONTENTS

MESA SPR – LILLY	50
Moderador: Maria José Santos	
• Jak/Stat pathway inhibition. A novel opportunity in RA management José M. Alvaro-Gracia	50
• Baricitinib – um novo paradigma na abordagem da Artrite Reumatóide Augusto Faustino	50
MESA SPR – SANOFI GENZYME	50
“Trends in Rheumatoid Arthritis”	50
Moderador: João Eurico Fonseca	
• Unmet needs in Rheumatoid Arthritis Maria José Santos	50
• Upcoming therapeutic approaches in RA: examples of head to head trials Robert Landewé	50
• Therapeutic alternatives for IL-6 blocking in RA: state of the art of sarilumab Blanca Hernandez-Cruz	50
MESA SPR – MSD	50
“Guidelines and clinical Practice – aiming at the best care”	50
Moderador: João Eurico Fonseca	
• EULAR 2016 Recommendations for RA & axSpA Management Sofia Ramiro	50
• Aiming at the best healthcare resources utilization Elsa Vieira de Sousa	50
• Physician and patient GAP Cátia Duarte	50
MESA SPR – PFIZER	50
“Signaling the Future in RA management”	50
Moderador: João Eurico Fonseca	
• Unmet needs & Jak pathways Robert Landewé	50
• From Clinical trials to real world data Bernard Combe	50
MESA SPR – BIOGEN	50
“From the bench to the bedside and beyond – opportunities and challenges using anti-TNF biosimilars”	50
• A brighter future? Biosimilars seen as an additional contribution to better medical outcomes and medical research João Eurico Fonseca	50
• Scientific/medical challenges – current situation and challenges that need to be address from a clinical perspective Maria Jose Cuadrado	50
• How can biosimilars fulfil all their potential in the treatment to improvement of patient’s lives? Filipe Araújo	51
MESA SPR – CELGENE	51
Moderador: Elsa Vieira de Sousa	
• PsA immunopathology: decoding the complex interplay in PsA Dennis McGonagle	51
• PsA clinical challenge: treating its complexity with PDE4 inhibition. Clinical experience in PsA with PDE4 inhibitor Jordi Gratacós	51

SUMÁRIO/CONTENTS

POSTERS

GRUPO 1	54
• P3 – Evaluating transfer of certolizumab pegol into breast milk: results from cradle, a prospective, postmarketing, multicenter pharmacokinetic study	54
• P24 – Certolizumab pegol is associated with long-term improvements in extra-articular manifestations of psoriatic arthritis over 4-years of treatment	56
• P64 – Effectiveness of early adalimumab therapy in psoriatic arthritis patients from REUMA.PT – Early PSA	57
• P62 – B-Cell subsets differences in inflammatory rheumatic diseases	59
• P190 – Patients with sensorineural hearing loss: benefits of a collaborative work for systemic evaluation – experience of a single tertiary-center	61
• P108 – The added value of a vasculitis clinic in a tertiary referral hospital	61
• P16 – ASAS health index for patients with spondyloarthritis: translation into portuguese, validation, and reliability	63
• P91 – Predictors of neuropathic pain in rheumatoid arthritis	64
GRUPO 2	65
• P170 – Zoledronate effectiveness and safety in active Paget’s disease: long-term follow-up and retreatment in clinical practice	65
• P22 – Methotrexate and low dose prednisolone downregulate osteoclast function in monocytes from early rheumatoid arthritis patients	66
• P86 – A comparison study of prevalence of traditional cardiovascular risk factors and Framingham Risk Score in systemic sclerosis patients and matched controls	67
• P172 – Avaliação da eficácia e segurança da fragmentação/aspiração ecoguiada de calcificação do ombro: resultados às 24 semanas	67
• P153 – Effectiveness and persistence of the first tumor necrosis factor inhibitor in portuguese psoriatic arthritis patients	68
• P174 – Cross-cultural validation of the eular “rheumatoid arthritis impact of disease” score into portuguese: a cross-sectional study of 288 RA patients using Rasch analysis	69
• P182 – Aplicação ecoguiada de plasma rico em plaquetas – uma solução na abordagem terapêutica da tendinopatia insercional crónica do tendão de Aquiles?	71
• P38 – Ultrasound-guided synovial needle biopsy: update of experience with an emerging, minimally invasive technique in clinical practice and research	72
GRUPO 3	73
• P28 – Pulmonary embolism in systemic sclerosis – one year follow up	73
• P140 – The physician global assessment criterion in SLE responder index does not present added value to define responders: a prospective cohort study	75
• P211 – Características clínicas e imunológicas da Síndrome de Sjögren precoce	75
• P55 – Prevalence of rheumatic diseases in a population of ANTIDFS70 positive patients	77
• P65 – Anti-müllerian hormone and ovarian reserve in systemic lupus erythematosus	77
• P128 – Lavado articular do joelho – uma alternativa terapêutica para a gonartrose e doença por deposição de cristais de pirofosfato de cálcio	78
• P143 – Análise descritiva de uma consulta reuma/derma: análise do ponto de vista da complexidade individual	79
GRUPO 4	80
• P127 – Níveis de vitamina D, avaliação da força e massa musculares e sarcopénia nos doentes com fratura da extremidade proximal do fémur	80

SUMÁRIO/CONTENTS

• P137 – Fatigue assessment in rheumatoid arthritis: agreement analysis between two scales (FACIT-F and RAID-fatigue)	81
• P138 – Statistical predictors of fatigue in patients with rheumatoid arthritis: a cross-sectional study	82
• P110 – Impact of psoriatic arthritis on psoriatic patient's quality of life – sub-analysis of PeSsoA, a patient reported outcomes study	83
• P204 – Redução da dose ou aumento intervalo de terapêutica biológica – experiência de um serviço	83
• P166 – Can the use of new technologies improve the use of patient reported outcomes (PROS) and patient participation in a national registry?	85
• P136 – New protein panel for rheumatic inflammatory diseases diagnosis	86
• P6 – Celastrol preserves bone structure and mechanics in arthritic rats	86
GRUPO 5	87
• P23 – A randomized, double-blind, placebo-controlled phase 3 study evaluating treatment strategies (continuation <i>versus</i> withdrawal) for maintaining low disease activity after 1 year of certolizumab pegol in DMARD-naïve patients with early and progressive, active	87
• P84 – Patient-centered aging biobanks – a survey on public perceptions and patient choice among rheumatology outpatients	89
• P122 – Do anxious or depressive rheumatoid arthritis patients on biotechnologic therapy have worse disease activity, function and quality of life?	90
• P90 – Median nerve ultrasound findings and clinical correlations in patients with systemic sclerosis: a comparative analysis with matched control subjects	91
• P43 – Predictors of mortality and re-fracture at 1 and 3 years after hip fracture	91
• P67 – Anxiety and depression on disease activity and quality of life of spondyloarthritis patients under biologic therapies	93
• P21 – ACPA seropositivity and peripheral natural killer cells as predictive markers of clinical response to rituximab in rheumatoid arthritis patients	94
• P69 – Real world data of rituximab effectiveness in rheumatoid arthritis: differences between biologic-naïve patients and previously exposed to biologics	95
GRUPO 6	95
• P159 – Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists <i>versus</i> switching to rituximab in patients with rheumatoid arthritis who failed previous TNF inhibitors	95
• P18 – Quality of life in patients with Behcet's disease	96
• P189 – Certolizumab pegol-like product mice equivalent reduces paws inflammation in TMTNF transgenic mice	97
• P214 – Existe desregulação imunitária na síndrome Sicca Não-Sjögren? Um estudo das subpopulações linfocitárias circulantes	98
• P173 – Osteoarthritis multidisciplinary clinic – 2 years of experience	99
• P146 – Are rheumatoid factor isotypes useful in the diagnosis of rheumatoid arthritis?	99
• P7 – Efficacy and safety of oral administration of pure celastrol in AIA rats	100
• P111 – Multidisciplinary Sjögren's Syndrome clinic: characterization and impact at the clinical and research level	101
GRUPO 7	102
• P27 – Lung involvement in rheumatoid arthritis – a portuguese reality	102
• P32 – Síndrome antifosfolípido: revisão de 52 casos de um serviço de reumatologia	103
• P160 – Percepção da doença numa consulta de reumatologia	104
• P186 – Status da vitamina D em doentes com artrite reumatóide e correlação com a atividade da doença	105

SUMÁRIO/CONTENTS

• P167 – “It can’t be zero”: a qualitative study of patients’ perspective on patient global assessment in rheumatoid arthritis	105
• P59 – The burden of spondyloarthritis – PAASPORT a population-based study	107
• P9 – Effects of tofacitinib in early arthritis bone loss	107
• P53 – Clinical outcomes of african patients from portuguese speaking countries evacuated for medical assessment in Portugal – rheumatology as a case study	108
GRUPO 8	109
• P56 – FRAX®port, osteodensitometria e prevenção das fraturas de fragilidade – a realidade de duas USF’s da zona centro	109
• P142 – Patient’s assessment of golimumab self-injection for inflammatory joint diseases treatment: a questionnaire-based survey	110
• P5 – Immunogenicity of biosimilars for the treatment of inflammatory rheumatic diseases: a review from confirmatory clinical trials	110
• P77 – Mycophenolate mofetil as an immunomodulatory for inflammatory eye disease: a case-series from a tertiary centre	112
• P101 – Fatigue and depression in patients with Behcet’s disease	113
• P124 – Translation and cross-cultural adaptation to european portuguese language of OAQOL: osteoarthritis quality of life	114
• P29 – Serum amyloid a levels as a potential biomarker to monitor psoriatic arthritis patients on biologics – a retrospective observational study	115
• P83 – Identification of sociodemographic factors in persistence/discontinuation of biological therapy in rheumatoid arthritis patients	115
GRUPO 9	117
• P150 – O papel da biópsia sinovial na avaliação diagnóstica de uma monoartrite	117
• P180 – Rituximab na artrite reumatóide: a experiência de um serviço de reumatologia	117
• P207 – Microarthroscopic guided synovial biopsies in rheumatology practice: benefits for the diagnosis and treatment of inflammatory arthritis patients	118
• P147 – Calcificação dos ligamentos peri-odontóides na doença por deposição de cristais de pirofosfato de cálcio	119
• P199 – Impact of different formulations of “patient global assessment” on remission classification by disease activity indices in rheumatoid arthritis	120
• P19 – Is immunohistochemistry useful to predict response to treatment in necrotizing myopathies?	121
• P176 – Redução da dose das terapêuticas anti-tnfa em doentes com artrite reumatóide: estudo transversal na prática clínica	122
• P10 – Early arthritis induces disturbances at bone nanostructural level reflected in decreased tissue hardness	123
GRUPO 10	123
• P78 – Translation and cross-cultural adaptation into european portuguese language of the coping instrument – CORS (Omgaan Met Reumatoide Artritis)	123
• P13 – Association of vitamin D status with rheumatoid arthritis disease activity and UV index	124
• P208 – As várias faces da Síndrome Sicca	125
• P87 – Neuropathic pain: association with skin thickness in systemic sclerosis patients	126
• P118 – Síndrome de Sjögren: casuística de um serviço de reumatologia e avaliação da atividade da doença aplicando o ESSDAI	127
• P197 – Ustekinumab no tratamento da artrite psoriática em doentes com psoríase moderada a grave. Experiência de um centro.	127

SUMÁRIO/CONTENTS

• P72 – Tratamento prévio com bifosfonatos: altera o efeito da teriparatide?	128
• P71 – Teriparatide na osteoporose: efeito independente da idade	128
GRUPO 11	129
• P161 – Acta Reumatológica Portuguesa: the rheumatologists' perspectives in 2017	129
• P50 – Efeito da terapêutica biotecnológica nas manifestações extra-articulares na espondilite anquilosante	130
• P202 – Overexpression of a nerve regeneration protein improves nociceptive behaviour in experimental OA	132
• P205 – What if we consider the physician visual analogue scale instead of patient in calculating CDAI and SDAI in a biologic pool of RA patients?	132
• P125 – Prevalência e associação de anticorpos específicos de miosite com polimiosite e dermatomiosite	133
• P37 – Lupus anticoagulant: an antibody possibly associated with sensorineural hearing loss in patients with systemic lupus erythematosus	133
• P133 – Lumbar multifidus myofascial stiffness in a healthy younger adult population: a pilot study from the Myospa project	134
• P103 – Neuropathic pain screening tools in rheumatoid arthritis: real world data	135
CASOS CLINICOS (CC)	
GRUPO 12	136
• CC183 – Nem toda a dor é fibromialgia	136
• CC60 – The many faces of IGG4-related disease: a case report with large vessel involvement and literature review	137
• CC198 – Manifestação cardíaca de doença de Behçet	138
• CC200 – Escleromalácia como manifestação rara de granulomatose com poliangéite	139
• CC66 – As potenciais faces das micobactérias	139
• CC97 – Artrite séptica: relato de um caso clínico raro	140
• CC121 – Xerostomia de etiologia atípica	141
GRUPO 13	141
• CC129 – Sarcoidose: dois casos clínicos com formas de apresentação a mimetizar espondilartrite	141
• CC132 – Artrite séptica por <i>streptococcus agalactiae</i> em doente com LES	142
• CC145 – Hyperphosphatemic familial tumoral calcinosis – a case report	143
• CC162 – Uma doença com “x” manifestações: histiocitose de células de langerhans (HCL)	144
• CC164 – “Só” vasculite, ou algo mais?	145
• CC175 – Cocaine associated vasculitis – a growing issue	146
• CC74 – Complicações potencialmente fatais na doença Still do adulto	147
GRUPO 14	147
• CC116 – Fibrodisplasia óssea e síndrome de mccune-albright: descrição de um caso clínico	147
• CC120 – Hipoacusia neurosensorial – uma manifestação rara de vasculite	148
• CC131 – Síndrome de Mikulicz como forma de apresentação de sarcoidose	149
• CC75 – Efficacy and safety of imatinib in systemic sclerosis – a curious case report	149
• CC193 – Basic crystal phosphate arthropathy diagnosed by ultrasound guided biopsy?	150
• CC46 – Uveíte como forma de manifestação de vasculite	151
• CC51 – RA cases of inpatients with suspected myocardial infarction diagnosis	152
GRUPO 15	152
• CC148 – Lúpus eritematoso sistémico e leucemia de linfócitos grandes granulares	152

SUMÁRIO/CONTENTS

• CC44 – Small vessel involvement in takayasu arteritis – what is the exact role for biologics?	153
• CC81 – Crioglobulinemia associada ao VIH: caso raro e desafio terapêutico	154
• CC88 – Is there a role for Anti-CD20 therapy in spondyloarthritis?	155
• CC158 – A mimetização de uma miosite: um caso de disferlinopatia	156
• CC123 – Linfocitose hemofagocítica como forma de apresentação de lúpus induzido por etanercept	156
• CC102 – Doença de Lyme e artrite – para além da sífilis, um outro grande imitador	157
GRUPO 16	158
• CC58 – Intravenous epoprostenol – a promising therapy in scleroderma digital vasculopathy	158
• CC82 – A importância da histologia na sarcoidose: a propósito de um caso atípico	159
• CC96 – Poems syndrome: 14 years without a diagnosis	160
• CC95 – Multiple musculoskeletal manifestations in post renal transplant hyperparathyroidism	161
• CC185 – Multidisciplinary approach of dactylitis: a diagnostic surprise!	161
• CC210 – Premenopausal osteoporosis: an unusual etiology	162
• CC113 – The importance of repeated ultrasound-guided synovial biopsies and histological analysis in a case of septic/psoriatic arthritis	163